canyon landscape

ALS Platform Trial

The purpose of this platform trial is to evaluate the efficacy of multiple study drugs at once, as compared with placebo, on ALS disease progression. New treatment regimens (drugs) will be added as they become available within the trial, meaning that multiple drug treatment regimens will be ongoing at all times during the platform trial. The BNI site is currently enrolling for 3 different drug regimens, Regimen A – Zilucoplan, Regimen B – Verdiperstat, and Regimen C – CNM-Au8, and will soon begin enrollment for a 4th regimen, Regimen D – Pridopidine. Additional regimens will be forthcoming across time. The placebo-controlled treatment period of the platform trial may last up to 24 weeks. After that, an optional open label extension period may be added per each separate regimen after completion of the placebo-controlled treatment period.

Principal Investigator: Shafeeq Ladha, MD

Enrollment Contacts:

Jessie Duncan
(602) 406-1466

Diana Thiessen
(602) 406-6606

Arubah Ahmed
(602) 406-4571

Open and enrolling subjects.
Primary Sponsor
Healey Center for ALS at Massachusetts General Hospital